US20060199268A1 - Method for assessing arteriosclerosis and diabetic nephropathy - Google Patents

Method for assessing arteriosclerosis and diabetic nephropathy Download PDF

Info

Publication number
US20060199268A1
US20060199268A1 US11/367,454 US36745406A US2006199268A1 US 20060199268 A1 US20060199268 A1 US 20060199268A1 US 36745406 A US36745406 A US 36745406A US 2006199268 A1 US2006199268 A1 US 2006199268A1
Authority
US
United States
Prior art keywords
platelet
serotonin level
serotonin
whole blood
level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/367,454
Other languages
English (en)
Inventor
Yuji Hirowatari
Katsuko Hara
Hakuo Takahashi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kansai Medical University
Tosoh Corp
Original Assignee
Kansai Medical University
Tosoh Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kansai Medical University, Tosoh Corp filed Critical Kansai Medical University
Assigned to TOSOH CORPORATION, KANSAI MEDICAL UNIVERSITY reassignment TOSOH CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HARA, KATSUKO, TAKAHASHI, HAKUO, HIROWATARI, YUJI
Publication of US20060199268A1 publication Critical patent/US20060199268A1/en
Priority to US12/046,106 priority Critical patent/US8142995B2/en
Priority to US13/359,097 priority patent/US20120122242A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/942—Serotonin, i.e. 5-hydroxy-tryptamine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/323—Arteriosclerosis, Stenosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/145555—Hetero-N

Definitions

  • the present invention relates to methods for assessing arteriosclerosis and diabetic nephropathy, which make it possible to know how serious arteriosclerosis or diabetic nephropathy.
  • Arteriosclerosis causes various diseases such as myocardial infarction, cerebral infarction, peripheral circulatory disorder, obstructive arteriosclerosis, peripheral neuropathy, visual disorder and nephropathy. Therefore, it is important to know how serious it is.
  • arteriosclerosis has been evaluated by measuring the thickness of the carotid-artery intima and media by ultrasonography (O'Leary D H et al., N Engl J Med, 340(1), p.
  • sphygmographs such as VaSera VS-1000 manufactured by Fukuda Denshi and Form PWV/ABI manufactured by Colin may be used, and for measurement of plethysmograms, plethysmographs such as Dinapulse SDP-100 manufactured by Fukuda Denshi and BC Checker manufactured by Future Wave may be mentioned.
  • Nephropathy is a common complication among diabetes patients and, in serious cases, requires lifelong hemodialysis treatment. The need for regular hospital visits for time-consuming hemodialysis treatment interferes with patients' daily life. Therefore, it is important to detect nephropathy early and prevent its progress chemotherapeutically to be in no need of hemodialysis treatment. Nephropathy is conventionally assessed by measuring creatinine (Yokota Tsukasa et al, Nihon Rinsho, suppl. Blood/Urine Chemical Examinations Immunological Testing (No. 1), p407(1989)) or urinary albumin (Current Medical vol. 43, Japanese Edition, Nikkei BP (2004)). Its earlier diagnosis and exact evaluation are demanded.
  • the above-mentioned method of evaluating arteriosclerosis has some problems with sensitivity and accuracy and, besides, requires special equipment. Therefore, there is demand for a simple method available with blood samples. Further, a method for early diagnosis of diabetic nephropathy is demanded, as mentioned above.
  • the present inventors found that patients with coronary disease show higher platelet-poor plasma serotonin levels and lower whole blood serotonin levels than healthy subjects (JP-A-2002-277461). It is considered that in arteriosclerotic lesions, specifically stimulated platelets release serotonin to increase the serotonin level outside platelets (platelet-poor plasma serotonin level), and subsequent consumption of serotonin in the arteriosclerotic lesions leads to decrease in the total blood serotonin level (whole blood serotonin level).
  • Arteriosclerosis is a main possible cause of diabetic nephropathy which occurs when renal capillaries are damaged. Therefore, blood serotonin level is highly promising as an index of nephropathy. Under these circumstances, the present inventors conducted extensive research and have accomplished the present invention.
  • the present invention provides a method for assessing arteriosclerosis comprising measuring the serotonin level in whole blood, serum or platelet-rich plasma and rating the serotonin level on such a scale that the lower it is, the more serious the arteriosclerosis is.
  • the present invention also provides a method for assessing diabetic nephropathy comprising measuring the serotonin level in whole blood, serum or platelet-rich plasma and rating the serotonin level on such a scale that the lower it is, the more serious the diabetic nephropathy is.
  • the present invention further provides a method for assessing diabetic nephropathy comprising measuring the serotonin level in platelet-poor plasma and rating the serotonin level on such a scale that the higher it is, the more serious the nephropathy is.
  • the present invention still further provides a method for assessing diabetic nephropathy which comprises a) measuring the whole blood, serum or platelet-rich plasma serotonin level in an individual; b) measuring the platelet-poor plasma serotonin level in the same individual; and c) rating the ratio of the platelet-poor plasma serotonin level obtained in b) to the whole blood, serum or platelet-rich plasma serotonin level obtained in a) on such a scale that the higher the ratio is, the more serious the diabetic nephropathy.
  • FIG. 1 shows the relationship between the IMT values and the whole blood serotonin levels obtained in Example 1.
  • FIG. 2 shows the whole blood serotonin levels in the respective groups obtained in Example 2.
  • FIG. 3 shows the platelet-poor plasma serotonin levels in the respective groups obtained in Example 2.
  • FIG. 4 shows the ratios of platelet-poor plasma serotonin level to whole blood serotonin level in the respective groups obtained in Example 2.
  • the present invention provides new indices for assessment of arteriosclerosis and diabetic nephropathy. Especially, it makes it possible to assess diabetic nephropathy and know its exact pathologic condition by measuring the serotonin levels both in whole blood, serum or platelet-rich plasma and in platelet-poor plasma. Further, it is also possible to assess diabetic nephropathy and know its exact pathologic condition from the ratio of platelet-poor plasma serotonin level to whole blood, serum or platelet-rich plasma serotonin level.
  • serum is the supernatant of blood obtained after coagulation and centrifugation. Because serotonin is released from platelets upon blood coagulation, serotonin in serum reflects serotonin in whole blood, i.e., total blood serotonin.
  • platelet-rich plasma means the supernatant of blood collected with an anticoagulant for inhibition of coagulation obtained after mild centrifugation.
  • the “mild centrifugation” means centrifugation under conditions that allow sedimentation of erythrocytes, but prevent sedimentation of platelets, for example, at 450 ⁇ g for 5 minutes.
  • Serotonin in platelet-rich plasma reflects serotonin in whole blood, i.e., total blood serotonin.
  • platelet-poor plasma means the supernatant of blood collected with an anticoagulant for inhibition of coagulation after severe centrifugation.
  • severe centrifugation means centrifugation under conditions that allow all hemocytes including platelets to sediment, for example, at 1,000 ⁇ g for 30 minutes.
  • the methods of the present invention require measurement of the serotonin level in whole blood, serum or platelet-rich plasma or the serotonin level in platelet-poor plasma.
  • the measurement may be done by any method without any particular restrictions, for example, by liquid chromatography or immunoassay.
  • liquid chromatography which is usually preceded by deproteinization of samples, it is common to use whole blood collected in a blood collection tube containing an anticoagulant as a sample.
  • a serum sample is usually used without deproteinization pretreatment of the sample.
  • IMT was compared with whole serotonin level, platelet-poor plasma serotonin level and the ratio of platelet-poor plasma serotonin level to whole blood serotonin and had a correlation only with blood serotonin level.
  • the results are shown in FIG. 1 .
  • the whole blood serotonin level showed significant decrease with increase in IMT (correlation coefficient ⁇ 0.37, significant difference 0.55).
  • the statistical analyses were performed with Spearman's rank correlation test.
  • the solid lines in FIG. 1 indicate the correlation line, the 95% confidence intervals and the 95% prediction intervals.
  • FIG. 2 indicates that whole blood serotonin level tends to be lower in the diabetic patients than in the healthy subjects and that among the diabetic groups, there was a tendency that whole blood serotonin level decreases with increase in creatinine.
  • FIG. 3 and FIG. 4 show that there are some cases in group 1 (creatinine at most 1.2 mg/dl) to group 4 (creatinine at most 6.0 mg/dl) which showed apparently higher values (platelet-poor plasma serotonin level of at least 20 mmol/l and a ratio of platelet-poor plasma serotonin level to whole blood serotonin level of at lease 5%) than healthy subjects (group 1).
  • group 1 creatinine level at most 1.2 mg/dl
  • group 5 included no patients with a platelet-poor plasma serotonin level of 20 mmol/l or above and a ratio of platelet-poor plasma serotonin to whole blood serotonin of 5% or above.
  • platelet-poor plasma serotonin level and the ratio of platelet-poor plasma serotonin level to whole blood serotonin level elevate at the initial phase of diabetic nephropathy and then return to normal as nephropathy progresses.
  • the present invention makes it possible to easily assess arteriosclerosis and diabetic nephropathy and is useful, especially in that it is possible to assess diabetic nephropathy and know its exact pathologic condition by measuring the serotonin levels both in whole blood, serum or platelet-rich plasma and in platelet-poor plasma. Further, it is useful also in that it is possible to assess diabetic nephropathy and know its exact pathologic condition from the ratio of platelet-poor plasma serotonin level to whole blood, serum or platelet-rich plasma serotonin level.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
US11/367,454 2005-03-07 2006-03-06 Method for assessing arteriosclerosis and diabetic nephropathy Abandoned US20060199268A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US12/046,106 US8142995B2 (en) 2005-03-07 2008-03-11 Method for assessing arteriosclerosis and diabetic nephropathy
US13/359,097 US20120122242A1 (en) 2005-03-07 2012-01-26 Method for assessing arteriosclerosis and diabetic nephropathy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005-062799 2005-03-07
JP2005062799A JP4559262B2 (ja) 2005-03-07 2005-03-07 動脈硬化および糖尿病性腎障害の判定方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/046,106 Division US8142995B2 (en) 2005-03-07 2008-03-11 Method for assessing arteriosclerosis and diabetic nephropathy

Publications (1)

Publication Number Publication Date
US20060199268A1 true US20060199268A1 (en) 2006-09-07

Family

ID=36168421

Family Applications (3)

Application Number Title Priority Date Filing Date
US11/367,454 Abandoned US20060199268A1 (en) 2005-03-07 2006-03-06 Method for assessing arteriosclerosis and diabetic nephropathy
US12/046,106 Expired - Fee Related US8142995B2 (en) 2005-03-07 2008-03-11 Method for assessing arteriosclerosis and diabetic nephropathy
US13/359,097 Abandoned US20120122242A1 (en) 2005-03-07 2012-01-26 Method for assessing arteriosclerosis and diabetic nephropathy

Family Applications After (2)

Application Number Title Priority Date Filing Date
US12/046,106 Expired - Fee Related US8142995B2 (en) 2005-03-07 2008-03-11 Method for assessing arteriosclerosis and diabetic nephropathy
US13/359,097 Abandoned US20120122242A1 (en) 2005-03-07 2012-01-26 Method for assessing arteriosclerosis and diabetic nephropathy

Country Status (4)

Country Link
US (3) US20060199268A1 (de)
EP (1) EP1701162B1 (de)
JP (1) JP4559262B2 (de)
DE (1) DE602006000603T2 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009141357A1 (en) * 2008-05-20 2009-11-26 Roche Diagnostics Gmbh Gdf-15 as biomarker in type 1 diabetes

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020052017A1 (en) * 2000-08-18 2002-05-02 Tosoh Corporation Diagnostic marker for vascular endothelial injury

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3215676B2 (ja) * 1994-04-20 2001-10-09 味の素株式会社 ピペリジン誘導体
JP4686933B2 (ja) * 2000-08-18 2011-05-25 東ソー株式会社 血管内皮障害の推定方法
JP4096780B2 (ja) * 2003-02-19 2008-06-04 東ソー株式会社 冠動脈攣縮型狭心症の識別方法
MY141862A (en) * 2003-07-22 2010-07-16 Arena Pharm Inc Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
JP2005062799A (ja) 2003-07-25 2005-03-10 Fuji Photo Film Co Ltd 光学補償シート、偏光板、及びそれを用いた液晶表示装置

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020052017A1 (en) * 2000-08-18 2002-05-02 Tosoh Corporation Diagnostic marker for vascular endothelial injury
US6485753B2 (en) * 2000-08-18 2002-11-26 Tosoh Corporation Diagnostic marker for vascular endothelial injury

Also Published As

Publication number Publication date
US20080160562A1 (en) 2008-07-03
JP2006242910A (ja) 2006-09-14
EP1701162A1 (de) 2006-09-13
JP4559262B2 (ja) 2010-10-06
DE602006000603D1 (de) 2008-04-17
DE602006000603T2 (de) 2009-03-26
US20120122242A1 (en) 2012-05-17
EP1701162B1 (de) 2008-03-05
US8142995B2 (en) 2012-03-27

Similar Documents

Publication Publication Date Title
Ginès et al. Hepatorenal syndrome
Horvath et al. Measurement of von Willebrand factor as the marker of endothelial dysfunction in vascular diseases
Iliou et al. Factors associated with increased serum levels of cardiac troponins T and I in chronic haemodialysis patients: Chronic Haemodialysis And New Cardiac Markers Evaluation (CHANCE) study
Chen et al. Does periodontitis reflect inflammation and malnutrition status in hemodialysis patients?
Letcher et al. Elevated blood viscosity in patients with borderline essential hypertension.
Miura et al. Urinary albumin excretion in heart failure with preserved ejection fraction: an interim analysis of the CHART 2 study
EP1946107B1 (de) Diagnose und beobachtung einer chronischen nierenkrankheit unter verwendung von ngal
US20100184089A1 (en) Diagnosis and monitoring of chronic renal disease using ngal
EP2021799A2 (de) Interleukin-33 (il-33) zur diagnose und vorhersage von herz-gefäss-erkrankungen
Zhu et al. High serum clusterin levels are associated with premature coronary artery disease in a Chinese population
Dessì et al. The usefulness of the prognostic inflammatory and nutritional index (PINI) in a haemodialysis population
Dong et al. Elevated Rho‐Kinase Activity as a Marker Indicating Atherosclerosis and Inflammation Burden in Polyvascular Disease Patients With Concomitant Coronary and Peripheral Arterial Disease
Azurmendi et al. Early renal and vascular changes in ADPKD patients with low-grade albumin excretion and normal renal function
Elkamshoushi et al. Serum endocan as a predictive biomarker of cardiovascular risk in erectile dysfunction patients
US8142995B2 (en) Method for assessing arteriosclerosis and diabetic nephropathy
Chowdhury et al. Microalbuminuria as a Predictor of Short-Term Mortality in Acute Ischemic Stroke.
Delcroix et al. NGAL usefulness in the intensive care unit three hours after cardiac surgery
JP6062439B2 (ja) 早期腎障害の評価マーカーとその測定方法
Yip et al. Time course of platelet activation and von Willebrand factor in patients with non-valvular atrial fibrillation after ischemic stroke evaluation of prognostic determinants
Fassett et al. Assessment of arterial stiffness, oxidative stress and inflammation in acute kidney injury
Kashani Acute kidney injury risk prediction
Aref et al. Evaluation of serum cyclooxygenase, hepcidin levels in acute renal injury (AKI) patients following cardiac catheterization
JP2020051911A (ja) 心不全マーカー
Abdulameer et al. NGAL as a biomarker in chronic kidney disease
Smith et al. Chronic Kidney Disease: Diagnosis and Assessment

Legal Events

Date Code Title Description
AS Assignment

Owner name: KANSAI MEDICAL UNIVERSITY, JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HIROWATARI, YUJI;HARA, KATSUKO;TAKAHASHI, HAKUO;REEL/FRAME:017646/0277;SIGNING DATES FROM 20060207 TO 20060215

Owner name: TOSOH CORPORATION, JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HIROWATARI, YUJI;HARA, KATSUKO;TAKAHASHI, HAKUO;REEL/FRAME:017646/0277;SIGNING DATES FROM 20060207 TO 20060215

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION